Skip to main content
. Author manuscript; available in PMC: 2022 Oct 26.
Published in final edited form as: Leukemia. 2022 Apr 26;36(6):1485–1491. doi: 10.1038/s41375-022-01580-7

Figure 1. Binding characteristics of new anti-CD123 mAbs.

Figure 1

A panel of anti-CD123 mAbs (11F11, 10C4, 7G3, 5G4, 1H8; used at 2 μg/mL) was tested flow cytometrically against parental RS4;11 cells (endogenously lacking CD123), RS4;11 cells transduced with human CD123, CD123-expressing human AML cells lines (TF-1, KG-1, MOLM-13), and MOLM-13 cells with CRISPR/Cas9-mediated knockout of the CD123 locus (CD123KO). Secondary antibody only negative control is shown as well.